stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Parexel International Corporation

United States · Privately owned

Parexel runs clinical trials and handles regulatory paperwork for drug, biotech, and medical device companies trying to get new treatments approved.

Parexel is a contract research organization, or CRO. Drug companies hire it to run the human testing that happens before a medicine can be sold. When a biotech has a promising molecule but no staff to manage a 500-patient trial across dozens of hospitals, Parexel steps in and does the work.

The job covers a lot of ground. Parexel helps design the trial, finds doctors and patients, tracks the data, and watches for side effects. It also handles the regulatory consulting: the giant stack of paperwork and meetings needed to persuade agencies like the U.S. Food and Drug Administration that a drug is safe and works. Its customers are pharmaceutical, biotechnology, and medical device companies, and it earns fees for each study and advisory project it takes on. The CRO industry is a scale business. Trials are expensive and slow, and drugmakers want a partner with global reach and deep experience, so they tend to pick from a small group of large firms. Parexel competes with rivals like IQVIA, Thermo Fisher Scientific (which owns the CRO PPD), and Labcorp. Its edge comes from decades of relationships with regulators and investigators, plus the sheer breadth of services it can bundle into one contract.


Parexel is no longer a public company. It was formerly listed on NASDAQ under the ticker PRXL, but in 2021 it was taken private by the private equity firm EQT, in a deal valued at roughly $8.5 billion. So today it is owned by private investors rather than traded on an exchange, and its financials are no longer reported to the public the way they once were.

Saved answer · last researched 15 Nov 2026